GL Capital, a healthcare-focused value-driven investment management group in China, has invested $12.5 million in UK-listed health technology platform Oxford BioDynamics (OBD).

GL Capital will take a 5 per cent stake in OBD, marking the Chinese firm’s first investment in Europe. The partnership will enable OBD to access the large market for personalized healthcare in China. OBD has appointed GL to act as the company’s lead mainland Chinese business development partner.

GL will apply its extensive industry network and local knowledge to identify, screen and recommend suitable business partners in China and these partners will benefit from access to OBD’s next-generation biomarkers.